Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL29157416 | 0.98 | CNR2 (0.49) | CNR2CYP2D6MAOAMAPK1ADRA1A | |
| SCHEMBL27527585 | 0.83 | ALDH1A1 (0.43) | CNR2MAOBCYP3A4TDP1ALDH1A1 | |
| SCHEMBL1337085 | 0.82 | CYP2A6 (0.65) | SCN9AMAOBCYP2A6CYP3A4TDP1 | |
| SCHEMBL4453342 | 0.82 | CNR2 (0.53) | CNR2CYP2A6ALDH1A1TP53CNR1 | |
| SCHEMBL7143579 | 0.80 | CYP2A6 (0.62) | SCN9AMAOBCYP2A6CYP3A4TDP1 | |
| SCHEMBL29489437 | 0.79 | CYP2A6 (0.68) | CNR2MAPK1CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL14055104 | 0.79 | CYP3A4 (0.48) | CYP2A6CYP3A4TDP1ALDH1A1TP53 | |
| SCHEMBL1250242 | 0.79 | CYP2A6 (0.68) | CNR2MAPK1CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL8307816 | 0.79 | MAP4K4 (0.50) | CNR2CYP2D6MAOAMAPK1ADRA1A | |
| SCHEMBL8308105 | 0.78 | CNR2 (0.50) | CNR2CYP2D6MAOAMAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714661-B1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-30 | — | — | EP | disclosed |
| US-8748624-B2 | Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-10 | — | — | US | disclosed |
| CN-103613527-A | N, N-substituted 3-aminopyrrolidine compounds useful as monoamine reuptake inhibitors | OTSUKA PHARMA CO LTD | 2014-03-05 | — | — | CN | disclosed |
| CN-103613587-A | N, N-substituted 3-aminopyrrolidine compounds useful as monoamine reuptake inhibitors | OTSUKA PHARMA CO LTD | 2014-03-05 | — | — | CN | disclosed |
| WO-2012162407-A1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | disclosed |
| US-20120302610-A1 | PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| US-20100185015-A1 | Process for preparing biaryls | BAYER CROPSCIENCE AG (DE) | 2010-07-22 | — | — | US | disclosed |
| CN-101175748-A | N, N-substituted 3-aminopyrrolidine compounds useful as monoamine reuptake inhibitors | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100185015-A1 | Process for preparing biaryls | AGPS, PAPSS1, BRPF1 | CNR2 2592/4885CYP2D6 385/4885MAOA 855/4885 |
| US-20120302610-A1 | PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GLP1R, GIPR, GCGR | CNR2 306/4885CYP2D6 2258/4885MAOA 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.